Colombia Non-invasive Prenatal Testing Market Size & Outlook, 2025-2033
Colombia Non-invasive Prenatal Testing Market Insights
- As highlighted in Reed Intelligence analysis, the Colombia Non-invasive Prenatal Testing Market, worth USD 20.57 Million in 2024, is forecasted to achieve USD 45.09 Million by 2033.
- The Colombia market is anticipated to grow at a CAGR of 9.11% during the period 2026–2033.
- By 2024, Consumables represented the largest share of the By Product Type market size.
- Instruments is expected to remain the key growth driver within By Product Type, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Colombia accounted for 0.48% of the global Non-invasive Prenatal Testing Market size in 2024.
- By 2033, United States is expected to remain the top global market in terms of size.
- Within LATAM, Brazil is forecasted to dominate the regional Non-invasive Prenatal Testing Market size by 2033.
- Mexico will be the fastest-growing market in LATAM, projected to achieve USD 173.89 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 20.57 Million |
| Market Size In 2033 | USD 45.09 Million |
| Largest segment | Consumables |
| Units | Revenue in USD Million |
| CAGR | 9.11% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Technology |
|
| By Application |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Colombia Non-invasive Prenatal Testing Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | XX.x | XX.x | XX.x | 12.85 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Instruments | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Colombia Non-invasive Prenatal Testing Market By Technology 2025-2033 (USD Million)
| By Technology | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Next Generation Sequencing (NGS) | XX.x | XX.x | XX.x | 8.24 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Microarray | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Polymerase Chain Reaction (PCR) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Colombia Non-invasive Prenatal Testing Market By Application 2025-2033 (USD Million)
| By Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trisomy | XX.x | XX.x | XX.x | 11.29 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Microdeletion Syndrome | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Colombia Non-invasive Prenatal Testing Market By End User 2025-2033 (USD Million)
| By End User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 11.75 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
